Antiretroviral Therapy–Induced Bone Loss Is Durably Suppressed by a Single Dose of Zoledronic Acid in Treatment-Naive Persons with Human Immunodeficiency Virus Infection: A Phase IIB Trial

BACKGROUND: Human immunodeficiency virus (HIV) infection and antiretroviral therapy (ART) are associated with bone loss leading to increased fracture rate among persons with HIV (PWH). We previously showed long-acting antiresorptive zoledronic acid (ZOL) prevented ART-induced bone loss through 48 we...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Infect Dis
Autori principali: Ofotokun, Ighovwerha, Collins, Lauren F, Titanji, Kehmia, Foster, Antonina, Moran, Caitlin A, Sheth, Anandi N, Lahiri, Cecile D, Lennox, Jeffrey L, Ward, Laura, Easley, Kirk A, Weitzmann, M Neale
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2019
Soggetti:
Articles and Commentaries
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7755092/
https://ncbi.nlm.nih.gov/pubmed/31621838
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/ciz1027
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi